ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IMM Immupharma Plc

2.25
0.07 (3.21%)
Last Updated: 12:58:05
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.07 3.21% 2.25 2.21 2.25 2.25 2.20 2.20 818,039 12:58:05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.97 7.5M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 2.18p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 3.78p.

Immupharma currently has 333,403,115 shares in issue. The market capitalisation of Immupharma is £7.50 million. Immupharma has a price to earnings ratio (PE ratio) of -1.97.

Immupharma Share Discussion Threads

Showing 14876 to 14898 of 39125 messages
Chat Pages: Latest  605  604  603  602  601  600  599  598  597  596  595  594  Older
DateSubjectAuthorDiscuss
21/2/2018
10:40
I tell you WQ are buying back here. 5k, 5k, 5k, 25k etc..... To the moon!
lodgeview
21/2/2018
10:38
I also think the once a month Lupuzor as distinct from the once a week Benlysta is going to address a key concern of regulators and the medical community - non compliance. Lupus is a life long affliction - Benlysta's long term beneficial effect data is shaky from trials to date - throw in once a week administration - so even if Lupuzor narrowly undershot Benlysta ( extremely unlikely IMHO) on efficacy over placebo the FDA might still approve it as its compliance rate would almost certainly be higher.
paxman
21/2/2018
10:38
Jeez this is gonna go through the roof!
lodgeview
21/2/2018
10:37
So why is this good ? For starters it works, if not for all patients, at least for a large majority of patients. That's the argument made by McCarthy but it is not the only one. It is as he rightly says, one more proof that Lupuzor is 100% safe.



Roll on £10

lucicavi
21/2/2018
10:37
25k bought
lucicavi
21/2/2018
10:30
"Biodistribution studies have shown that it concentrates in the lung and in the spleen, ie in regions rich in antigen presenting cells (APCs), which in turn target other cells of the immune system." Bang on. Exactly what I posted yesterday and, as far as I have read on this board, an under appreciated point. It concentrates in the spleen - hence small molecule, small dose, no identified side effects, targeted placement of active material = efficacy and safety :)
wigwammer
21/2/2018
10:29
£200
ballsac
21/2/2018
10:28
Deep sigh.
hamhamham1
21/2/2018
10:28
So why is this good ? For starters it works, if not for all patients, at least for a large majority of patients. That's the argument made by McCarthy but it is not the only one. It is as he rightly says, one more proof that Lupuzor is 100% safe.





EXCITEMENT!!!!!!!

lucicavi
21/2/2018
10:26
£50 and more.
stealth wealth
21/2/2018
10:25
News coming


500p soon. Bring it on babies

lucicavi
21/2/2018
10:22
Wow Lodgeview has your doctor put you on the happy pills.
13th Feb with the share price @126 you were "Bloody worried I'm losing thousands."
Today with share price @ 126 "the only way is up, get in while you can"
That's some turn around.

kevioio
21/2/2018
10:20
top tips #14869

We already know Lupuzor beats Benlysta on efficacy. The evidence is staring us all in the face from the superb Phase 2b results.

This it what we could be on for in Phase 3 and beyond, improvement rates with Lupuzor (target group):

Phase 2b at 3 months = + 67.6%
Phase 2b at 6 months = + 84.2%
Phase 3 at 9 - 12 months = + 100% ??
Follow-up study = + 100% ??

For me its not now about whether lupuzor works but just how big the improvement will be at 9 and 12 months, and in the follow-up.

N.B.
Resetting the Autoreactive Immune System with a Therapeutic Peptide in Lupus
Prof. Sylvian Muller
Lupus (2015) 24, pg 412–418

"The phase IIb trial showed that after three months of therapy (three subcutaneous injections of 200 ug peptide/patient in addition to standard of care), Lupuzor improved Systemic Lupus Erythematosus Disease Activity Index score of lupus patients under active treatment by 67.6% versus 41.5% in the placebo group (p<0.025). After three additional months of follow-up, the improvement rate was 84.2% versus 45.8% (p<0.025). The side effect profile was unproblematic and the drug was well tolerated as evidenced by a very low drop-out rate."

professor bang bang
21/2/2018
10:16
This is another post from him which is worth a read too

"15 years since S muller started working with peptides in targeting lupus "

and we are now this close to the final staretch

From Jan22 2018
I have voiced concern in the past about the ability of management to maximise the value of Lupuzor. That led me to write at some point: if they do a deal before the data read out I'll sue them ! If anything, this underlines my confidence in the success of the product.

Dosing: I do not see an issue here.
15 years ago, when S Muller started working with peptides in targeting lupus, she was looking to modulate auto-reactive T/B cells. That was the idea, getting away from systemic immunosuppressant and look for something more specific. She screened the 60 or so known auto antigens present in lupus and by pure serendipity, with no pre existing knowledge of how or why, realised that the phosphorylated version of one them had a clinical benefit in animal models. From then on she engaged into a multi year exercise of reverse engineering to try and elucidate the mode of action. At the beginning the compound was used intravenously, but also sub cutanously and even intra nasaly. Over the years it was an iterative process to find the right amount, the right route of delivery and the right frequency. The phase 2 has clearly established the dose (200), the route (sc) and the frequency (1x/month). It is exactly that regimen that is used in the phase 3 and it is if anything very reassuring.
Final comment on dosing: Lupuzor targets cells of the immune system, it doesn't target "all the cells in the body" as I read somewhere. Biodistribution studies have shown that it concentrates in the lung and in the spleen, ie in regions rich in antigen presenting cells (APCs), which in turn target other cells of the immune system. Even in the absence of toxicity, in complex biological processes with feedback loops, the highest clinical benefit isn't necessarlly at the highest dose.

Trehalose and the failed Chephalon trial:
S Muller published her paper on the detrimental impact of trehalose on Lupuzor back in 2014.(link in my previous post). Her findings were that Lupozor downregulates autophagy and trehalose upregulates autophagy. Since then new, broad based and independent research has confirmed this, as opposed to suggestions otherwise. In 2016 the article with the title "Mystery solved: Trehalose kickstarts autophagy by blocking glucose transport" was published in Sciences hxxp://alturl.com/ykjom
I think that this should kill the argument and explain why the Cephalon ph2 study failed back in the days.

chalky230
21/2/2018
10:13
This was posted on LSE chat by NKOTBUK just after IMM anounced the extention

He is a very knowledgable person and fully understands the science of lupuzar more than i do , but its woth a read

I hope he doesnt mind me posting it , or you can see on lse

from Jan 18th 2018
this is obviously very good news, but I have to say I don't buy for one second that "this came as a total surprise to the company". The plan has been in the drawer from day one and needed only the slightest nudge to get out of it. I have no doubt that the "demand" was there, but the "supply" also. Don't get me wrong, it is a good thing that the company hadn't mentioned it so far. I'll explain in a minute.
Why is it not a surprise ? Because there is a precedent ! Back in 2010, when Cephalon was preparing their own ph2 (the screwed one with the wrong excipient !), the open label extension was announced almost at the same time. The FDA trial records are quite clear on that point. Both original RCT ph3 trial (6 months) and open label extension (12 months) were posted in 2010.
hxxps://clinicaltrials.gov/ct2/results?cond=&term=CEP-33457&cntry=&state=&city=&dist=
So why is this good ? For starters it works, if not for all patients, at least for a large majority of patients. That's the argument made by McCarthy but it is not the only one. It is as he rightly says, one more proof that Lupuzor is 100% safe. For a compound that is going to be used for the rest of your life, that is vitally important. Lupuzor has never been tested for so long in man, 18 months for the active arms. Cephalon terminated the extension trial shortly after the 6 months read-out and Immupharma in their own ph2b never treated longer than 3 months (3m active but 3 months follow up). From 3 to 18 months, that's a big jump, very very valuable from the standpoint of regulators. And this data will have matured and be available to the FDA upon filing. But not only safety data can be extracted from the extension. The first few patients who got randomized, that's back in early 2016, went off the drug early 2017. That's almost 1 year, how about that for a wash out period ! These patients can almost be considered as their own control ! Super cool. We'll also get a better sense of the absolute level of the plateau and the latency of the treatment post interruption. Also it means that their commercial readiness is well advanced (you need 100% of the stuff you used in the first part of the trial). We as investors might even feel more confident about efficacy before the readout, the highest the participation rate (if this gets communicated, which I doubt to be honest). And last but not least, by announcing the extension only now, they haven't introduced an upward bias in the placebo effect. All of this is almost too good to be true. See you in 4 to 6 weeks time for the primary endpoint read out, Enjoy.

chalky230
21/2/2018
10:08
Liking the chart action. Broken through two resistance levels next one circa 135-140. Seems a fair target to reach ahead of the tri results, who would want to sell now?!
rathean
21/2/2018
10:05
Every big pharma and his dog will want into IMM on good results.
englishlongbow
21/2/2018
10:05
I see a takeover for £50 on good results:

Forecasts for M&A activity among pharmas to excede $200 billion for 2018

"EY is confident this year’s deal value will exceed $200 billion, given companies’ increased financial firepower and balance sheet strength. There is also substantial pent-up demand, with 60 percent of life sciences executives surveyed in October 2017 planning to actively pursue M&A in the next 12 months."

englishlongbow
21/2/2018
10:04
Its a coiled spring now.
englishlongbow
21/2/2018
09:58
This one 144 by end of week
costax1654x
21/2/2018
09:56
Newcomers need to be aware data suggests IMM's P140 platform (from which Lupuzor derives) could treat several other indications, not just lupus, so adding hugely to its value:

Lupuzor Symposium - Sylvianne Muller (Jun 2016)
41 min 40 sec onwards:



- Systemic Lupus Erythematosus (SLE) (Lupuzor reports Phase 3, Q1 2018)
- Neuropsychiatric lupus (NPSLE)
- Gougerot-Sjagren syndrome (GSS) (Market size $2.2 bn by 2024)
- Rheumatoid Arthritis (Market size $28.5 bn by 2025)
- Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022)
- Guillan-Barre disease
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Asthma (Market size $20.7 bn in 2015)

Other potential evaluations (to be tested Jun 2016 onwards):
- Scleroderma (Systemic Sclerosis, Raynaud)
- Psoriasis
- Multiple Sclerosis (MS) (Market size $20 bn by 2024)
- (Others to follow)

englishlongbow
21/2/2018
09:55
Remember WQ have to buy back 0.5% of the company at some point could get interesting.
blackbear
21/2/2018
09:42
Thanks for the heads up chalky et al.



IMM discussed from about 30mins - nothing new but good to hear the bull case for investing in IMM again

Lanstead involvement 36:00 to 38:30 - is worth listening to. They of course still hold around 5% of IMM and took part in the last fund raise.

metis20
Chat Pages: Latest  605  604  603  602  601  600  599  598  597  596  595  594  Older

Your Recent History

Delayed Upgrade Clock